Central Nervous System (CNS) Disorders
The company’s first line of products is based on issued US and foreign patents acquired through Prismic’s purchase of the assets of Scarista Ltd. in 2011. Scarista held the worldwide license rights to this portfolio in the area of Central Nervous System (CNS) disorders. Prismic’s lead product is NEUREPA TM, a unique patented formulation of an Omega-3 triglyceride concentration that is 92% EPA. NEUREPA TM was formulated and developed specifically to address the Omega-3 deficiency in patients suffering from depression, bi-polar disorder, and schizophrenia.
Line extensions of NEUREPA TM are also currently being formulated for other related patient populations and conditions.
Prismic’s second line of products is based on Palmitolyethanolamide (PEA), an endogenous fatty acid amide. Prismic acquired the worldwide rights to PEA and the extensive portfolio of issued and pending US and international patents from Epitech SpA. The patent portfolio covers PEA alone and in combination with other molecules across a broad array of medical conditions. Prismic’s rights cover all indication areas and all regulatory categories including prescription drugs, medical foods and nutritional supplements.
PEA is a molecule with over five decades of use and is supported by substantial clinical and safety data. PEA is of particular interest because of recent data indicating that this molecule displays anti-inflammatory, anti-fibrotic, and analgesic properties that would allow it to serve as a renal-sparing anti-inflammatory. There is also early data that suggests that PEA may, potentially, reduce proteinuria.
Prismic has two lead products in development derived from PEA.
Peripheral Neuropathic and Other Chronic Pain Conditions
Existing clinical experience suggest that PEA also has significant potential in addressing peripheral neuropathy and chronic pain, arthritic syndromes and nerve entrapment syndromes. Other data suggest promise for the treatment of elevated intraocular pressure (IOP), diabetic retinopathy, and macular degeneration.
Prismic plans to out-license or partner PEA internationally on a country-by-country basis, and possibly by indication area.